Form SCHEDULE 13G REGENXBIO Inc. Filed by: JPMORGAN CHASE & CO
Alpha Vantage · StreetInsider · · AI-summarised by FinFlash
JPMorgan Chase & Co. filed a Schedule 13G with the SEC, reporting beneficial ownership of 3,560,915 shares of REGENXBIO Inc. common stock, representing 5.3% of the class. The filing indicates JPMorgan Chase & Co. has sole voting power over 3,324,340 shares and sole dispositive power over 3,560,915 shares.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.